Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Lactose celecoxib pharmaceutical composition

A technology of celecoxib and composition, applied in the pharmaceutical field, can solve problems such as high elasticity

Inactive Publication Date: 2015-12-23
TIANJIN JINYAO GRP
View PDF8 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the solid dispersion has high elasticity and is not easily crushed into particles.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lactose celecoxib pharmaceutical composition
  • Lactose celecoxib pharmaceutical composition
  • Lactose celecoxib pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Dissolve the solid α-lactose monohydrate and celecoxib completely in 55% ethanol aqueous solution (55% of the volume ratio of ethanol) at 60°C, and distill under reduced pressure until the ethanol content in the ethanol aqueous solution is 30-35%, -10 to - Freeze at 5°C, filter, and dry the solid in a vacuum oven under reduced pressure. The ratio of α-lactose and celecoxib is shown in the table below. The α-lactose and celecoxib solid dispersions are simply pulverized and passed through the No. 2 sieve, and the D90 particle size is measured by a laser particle size analyzer, and then pulverized twice by a jet mill, the pulverization time is 10 minutes / time, and then used The D90 particle size of the powder is measured by the laser particle size analyzer, and the difference between the two is obtained by subtracting the D90 particle size.

[0032]

[0033]

[0034] Examples 1-1 to 1-5 have melting points between 166-173°C.

Embodiment 2

[0036] Dissolve the solid α-lactose monohydrate and celecoxib completely in 55% ethanol aqueous solution (55% of the volume ratio of ethanol) at 60°C, and distill under reduced pressure until the ethanol content in the ethanol aqueous solution is 30-35%, -10 to - Freeze at 5°C, filter, and dry the solid in a vacuum oven under reduced pressure. The ratio of α-lactose and celecoxib is shown in the table below. The solid dispersion of sodium lauryl sulfate, α-lactose, and celecoxib is passed through No. 2 sieve after being simply pulverized, and the D90 particle size is measured with a laser particle size analyzer, and then pulverized twice by a jet mill, and the pulverization time is 10 minutes / time, and then use a laser particle size analyzer to measure the D90 particle size of the powder, and subtract the two to get the D90 particle size difference. .

[0037]

[0038] Examples 2-1 to 2-5 have melting points between 161-170°C.

Embodiment 3

[0040] Dissolve the solid α-lactose monohydrate and celecoxib completely in 55% ethanol aqueous solution (55% by volume of ethanol) at 60°C, distill under reduced pressure until the ethanol content in the ethanol aqueous solution is 30-35%, -10 to - Freeze at 5°C, filter, and dry the solid in a vacuum oven under reduced pressure. The ratio of α-lactose and celecoxib is shown in the table below. The α-lactose and celecoxib solid dispersions are simply pulverized and passed through the No. 2 sieve, and the D90 particle size is measured by a laser particle size analyzer, and then pulverized twice by a jet mill, the pulverization time is 10 minutes / time, and then used The D90 particle size of the powder is measured by the laser particle size analyzer, and the difference between the two is subtracted to obtain the D90 particle size difference.

[0041]

[0042]

[0043] Examples 3-1 to 3-5 have melting points between 170-178°C.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Melting pointaaaaaaaaaa
Melting pointaaaaaaaaaa
Melting pointaaaaaaaaaa
Login to View More

Abstract

Belonging to the field of pharmacy, the invention relates to a lactose celecoxib pharmaceutical composition and a preparation method. The composition is characterized in that lactose and celecoxib form solid dispersions by means of coprecipitation.

Description

technical field [0001] The invention belongs to the field of pharmacy, and relates to a pharmaceutical composition and preparation method of lactose celecoxib, which is characterized in that the lactose celecoxib forms a solid dispersion through a co-precipitation method. Background technique [0002] Celecoxib is a type Ⅱ cyclooxygenase (COX-2) inhibitor that can selectively act on type Ⅱ cyclooxygenase and is widely used clinically for osteoarthritis and rheumatoid arthritis. inflammation treatment. [0003] Patent CN99802185.7 discloses that this compound is almost insoluble in water, and this substance also has some other obvious properties and characteristics, such as its crystallization as needles, which brings its cohesiveness, low bulk density and low compressibility These characteristics all determine that such celecoxib has poor fluidity and compressibility, and is not easily crushed into smaller particles. [0004] In order to solve the problems of poor solubili...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/14A61K47/26A61K31/635A61P19/02A61P29/00
Inventor 孙亮
Owner TIANJIN JINYAO GRP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com